9 January 2019

Oculis SA, a clinical-stage biopharmaceutical company developing next-generation topical ophthalmic treatments in Lausanne, has entered into an agreement to in license a novel topical anti-TNF alpha antibody from Novartis. The compound, named LME 636 which will be renamed OCS-02, is based on a proprietary single-chain antibody fragment technology specifically designed for topical delivery.

The VISCHER-team advising Oculis is led by Christian Wyss (Partner) with Vincent Reardon (Senior Associate) and Vera Keller (all Corporate) and Adrian Briner (Associate) Tax.

Categories: Corporate and Commercial, Health Care, Intellectual Property, Real Estate, Information and Communication Technology, Antitrust and Competition, Life Sciences, Pharma, Biotech

You are currently offline. Some pages or content may fail to load.